SCHEMBL17066473

SCHEMBL17066473

Cc1ccc(-n2cc(C)cn2)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 1/20 0.47
KDM4E B2RXH2 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
RAB9A P51151 3/20 0.40
HTT P42858 3/20 0.39
ALDH1A1 P00352 3/20 0.38
NPC1 O15118 2/20 0.37
PIP4K2A P48426 1/20 0.37
LMNA P02545 1/20 0.37
PKM P14618 1/20 0.37
NPBWR1 P48145 1/20 0.36
HCAR1 Q9BXC0 1/20 0.36
POLB P06746 1/20 0.36
COMT P21964 1/20 0.36
TDP1 Q9NUW8 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17666300 0.81 GCG (0.40) KDM4ENPSR1MAPTRAB9AHTT
SCHEMBL17666282 0.79 NPSR1 (0.38) KDM4ENPSR1MAPTMAPK1RAB9A
SCHEMBL17066470 0.78 TDO2 (0.49) TDO2KDM4ENPSR1MAPTMAPK1
SCHEMBL16277507 0.76 CSNK2A1 (0.46) TDO2KDM4ENPSR1MAPTMAPK1
SCHEMBL22011261 0.73 ALDH1A1 (0.39) KDM4EMAPTMAPK1RAB9AALDH1A1
SCHEMBL2709538 0.73 RXRA (0.45) KDM4EMAPTMAPK1RAB9AHTT
SCHEMBL16202089 0.73 KDM4E (0.46) KDM4ENPSR1MAPTHTTALDH1A1
SCHEMBL17710261 0.73 NOTUM (0.45) TDO2KDM4ENPSR1MAPTMAPK1
SCHEMBL10264757 0.73 TDO2 (0.44) TDO2KDM4ENPSR1MAPTMAPK1
SCHEMBL31284838 0.73 TDO2 (0.51) TDO2KDM4ENPSR1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023218023-A1 THIAZOLOARYL-METHYL SUBSTITUTED CYCLIC HYDRAZINE-N-CARBOXAMIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2023-11-16 WO disclosed
US-20160339032-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-11-24 US disclosed
US-9446046-B2 Tetrahydropyrazolopyrimidine compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-09-20 US disclosed
US-20160030430-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-02-04 US disclosed
US-9126999-B2 Tetrahydropyrazolopyrimidine compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160030430-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS SSB, TLR8, TLR9 TDO2 3200/4885KDM4E 1640/4885NPSR1 1247/4885
US-20160339032-A1 TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS SSB, TLR8, TLR9 TDO2 3200/4885KDM4E 1640/4885NPSR1 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.